	US 11,701,340 B2
	Liquid pharmaceutical compositions
Anish Dhanarajan, Catonsville, MD (US); and Francesca Minale, Catonsville, MD (US)
Assigned to VICI HEALTH SCIENCES., LLC, Elkridge, MD (US)
Filed by Vici Health Sciences LLC, Elkridge, MD (US)
Filed on Apr. 17, 2020, as Appl. No. 16/851,242.
Claims priority of provisional application 62/835,123, filed on Apr. 17, 2019.
Prior Publication US 2020/0330431 A1, Oct. 22, 2020
Int. Cl. A61K 31/135 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61P 25/16 (2006.01); A61K 31/404 (2006.01)

CPC A61K 31/404 (2013.01) [A61K 9/08 (2013.01); A61K 31/135 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01)]

3 Claims

1. A liquid pharmaceutical composition comprising about 0.03% w/v rasagiline mesylate, about 53% w/v water, about 60% w/v glycerin, from about 0.06% to about 0.16% w/v citric acid, from about 0.06% to about 0.5% w/v of a citrate salt, about 0.18% w/v methylparaben and about 0.02% w/v propylparaben, wherein w/v denotes weight by total volume of the composition.